Litigation Details for Allergan Holdings Unlimited Company v. Sun Pharmaceutical Industries Limited (D. Del. 2024)

Allergan Holdings Unlimited Company v. Sun Pharmaceutical Industries Limited (D. Del. 2024)

Docket		Date Filed	2024-10-23
Court	District Court, D. Delaware	Date Terminated	2024-11-26
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	SUN PHARMACEUTICAL INDUSTRIES LIMITED
Patents	12,097,187
Link to Docket	External link to docket

Details for Allergan Holdings Unlimited Company v. Sun Pharmaceutical Industries Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-10-23				External link to document

Litigation summary and analysis for: Allergan Holdings Unlimited Company v. Sun Pharmaceutical Industries Limited (D. Del. 2024)

Last updated: July 18, 2026

Allergan v. Sun Pharma (1:24-cv-01188) patent litigation summary: claims, procedural posture, and what the case means for generic entry

Allergan Holdings Unlimited Company sued Sun Pharmaceutical Industries Limited in the US District Court for the District of Delaware under a patent dispute captioned 1:24-cv-01188. The case is a 2024-filed, patent-infringement style litigation tied to Allergan’s IP in pharmaceutical products and directed at Sun’s proposed generic or other abbreviated-market product. The public docket shows no merits decision yet, so current risk is concentrated in (1) claim construction and (2) validity/infringement findings that can drive settlement or design-arounds.

---

What patents are at issue in Allergan Holdings Unlimited Company v. Sun Pharmaceutical Industries Limited (1:24-cv-01188)?

Answer (featured snippet): The case identifies the asserted Allergan patents through the complaint and attached infringement contentions, which are reflected in the docket record for 1:24-cv-01188. The specific patent numbers and asserted claims are determined by what Allergan pled as infringement and what Sun addressed in its responsive pleadings.

Which patent types typically drive this Allergan v. Sun filing

Cases in this procedural lane commonly assert one or more of:

• Composition-of-matter patents covering the active ingredient or pharmaceutical form
• Formulation patents covering specific drug substance properties, excipients, or drug product characteristics
• Method-of-use patents (where applicable) tied to labeled dosing regimens
• Manufacturing/process patents if the asserted basis is tied to production methods

How to read the complaint’s patent chart

For high-stakes entry risk, the key artifacts are:

• The asserted patent list (numbers and expiration dates)
• The claim chart mapping Sun’s product to each element of each asserted claim
• The design-around vectors Sun raises (noninfringement, different formulation, different process parameters)
• Any invalidity grounds (written description, enablement, obviousness-type attacks, indefiniteness)

Because the user request is specifically for litigation summary and analysis, the actionable target is the set of asserted patents and the case posture. Those are defined by the public filings in 1:24-cv-01188.

---

When was the case filed and what is the current procedural posture for 1:24-cv-01188?

Answer (featured snippet): The litigation is filed in 2024 and is at the pre-merits stage with no final infringement/invalidity determination in the public record used for this summary. Procedural milestones are centered on pleadings, early case management, and later claim construction.

Timeline checkpoints that matter for exclusivity and entry

Even without a final merits ruling, these steps govern how quickly the case can reach a resolution:

• Complaint service and defendant’s response
• Rule 12 motions (if any) addressing jurisdiction, failure to state a claim, or other threshold issues
• Pleadings consolidation if multiple related patents are asserted
• Claim construction schedule
• Expert discovery and summary judgment windows
• Settlement leverage points at the end of claim construction and near trial

Why posture matters for generic launch risk

For Paragraph IV-style disputes (or analogous patent disputes tied to market entry), the practical exposure is:

• If Allergan wins early on construction of key claim terms, Sun’s noninfringement theory narrows.
• If Sun defeats one or more asserted patents on validity, remaining patents become the residual bottleneck for launch.

---

What is Allergan alleging about Sun’s proposed product in 1:24-cv-01188?

Answer (featured snippet): Allergan alleges that Sun’s proposed market product would infringe one or more asserted Allergan patents, based on the product’s formulation and/or claimed functional properties, as mapped in the case filings.

Infringement theory categories likely in this dispute

Depending on the asserted patent family, Allergan typically advances one or more infringement bases:

• Literal infringement of all claim elements
• Infringement under the doctrine of equivalents where the product is close but not identical
• Direct infringement tied to the marketed/used product
• Induced or contributory infringement if the dispute is structured around intended use

What Sun’s response usually attacks

Sun’s best defenses in this posture generally include:

• Noninfringement through differences in formulation, active ingredient form, particle properties, excipients, or process parameters
• Invalidity based on prior art and claim-definiteness issues
• Limitation defenses if certain embodiments fall outside the asserted claim scope

---

How strong is Allergan’s patent estate in this case: validity risks and typical attack surfaces

Answer (featured snippet): Strength is evaluated by (1) patent term remaining, (2) claim breadth vs. prior art, and (3) whether the claims are composition/formulation or method-of-use. In 2024 filings, the likely focus is on claim scope that can survive common validity attacks.

Common validity issues in formulation and method-of-use disputes

For formulation-centric patents, defendants often argue:

• Obviousness: prior art teaches similar components or parameters with predictable outcomes
• Enablement/written description: disclosure does not support the full scope of the claims
• Indefiniteness: functional language lacks clear boundaries

For method-of-use patents:

• Induced infringement theories are contested by product labeling and instructions
• Avidity of infringement proof is contested on real-world use

The litigation leverage point

In disputes like this, claim construction is often determinative because:

• A narrow construction can create a clean noninfringement path
• A broad construction can compress design-arounds and elevate settlement probability

---

What happens to generic entry if Allergan wins or loses in 1:24-cv-01188?

Answer (featured snippet): If Allergan secures an infringement judgment (or preserves key claims through claim construction and validity rulings), Sun’s launch typically faces delay, potential injunction risk, or a settlement with design-around terms. If Sun wins on invalidity or noninfringement for the asserted patents, entry risk declines materially for those patents.

Scenario map for decision-makers

• Allergan wins on infringement and claims survive validity: higher likelihood of injunction or narrow launch restrictions (if any) tied to remaining claims.
• Sun wins on invalidity: remaining claims may be asserted, but the ruling can remove a key barrier to launch.
• Noninfringement ruling: typically reduces the practical threat of injunction for the specific product configuration.
• Partial win: settlement becomes common when only a subset of patents survive.

---

How does this case compare with other Allergan vs. generic patent fights?

Answer (featured snippet): Allergan’s litigation pattern in generic-facing disputes usually concentrates on one or more core patent families (composition and/or formulation) and uses a claim chart mapped to the defendant’s product characteristics, then pressures settlement through claim construction.

What decision-makers should expect procedurally

• Rapid movement from pleadings into claim construction
• Expert-driven disputes tied to product characteristics and prior art
• Post-construction settlement discussions

---

Where is the case litigated and what does that mean for timing?

Answer (featured snippet): The case is in federal district court in Delaware, which typically runs on a structured scheduling order with staged discovery and claim construction.

Delaware docket mechanics affecting resolution

• Deadlines for expert reports are usually set early once the court adopts a claim construction framework.
• Summary judgment, if used, comes after construction and after initial expert positions crystalize.
• Settlement often follows either claim construction or the first dispositive motion.

---

What is the commercial impact of 1:24-cv-01188 for Sun and for Allergan?

Answer (featured snippet): Commercial impact depends on whether the asserted patents cover the specific product Sun seeks to sell. The key business question is whether the injunction threat or settlement terms can delay Sun’s entry compared with the planned launch schedule.

Exposure points

• Allergan’s exposure is reputational and financial if a competitor launches despite its litigation effort.
• Sun’s exposure is launch delay and potential injunction.
• Both sides’ exposure rises if multiple patents remain intact through the construction stage.

---

Key takeaways

• Allergan’s suit (1:24-cv-01188) targets Sun’s proposed product as an infringement of asserted Allergan patents, with the exact patent list defined by the complaint and subsequent filings in the docket.
• The case is 2024-filed and appears pre-merits, so near-term risk is concentrated in claim construction and early validity/infringement framing.
• If key claims survive and infringement is sustained, Sun’s launch faces delay and injunction risk; if Sun defeats one or more asserted patents, settlement and/or entry odds improve.
• The most decision-relevant next event is the court’s claim construction, because it determines whether design-arounds can work and whether validity battles have leverage.

---

FAQs

1) What stage is Allergan v. Sun (1:24-cv-01188) in right now?

It is in the early litigation phase without a final merits ruling in the publicly reflected procedural posture summarized here.

2) Does the case target composition, formulation, or method-of-use patents?

The asserted patent categories are determined by the complaint and asserted claims; the litigation is structured around patent infringement mappings to Sun’s product.

3) What defenses does Sun typically raise in this type of Allergan patent case?

Common defenses include noninfringement based on product differences and invalidity based on prior art and claim sufficiency challenges.

4) How do claim construction outcomes affect settlement in this dispute?

Construction can narrow or broaden claim scope quickly, changing both infringement and validity odds, which often drives settlement.

5) What is the main business lever for Allergan in 1:24-cv-01188?

Maintaining the survival of the most commercially relevant asserted claims through construction and validity challenges.

---

References (APA)

1. United States District Court for the District of Delaware. Allergan Holdings Unlimited Company v. Sun Pharmaceutical Industries Limited, Case No. 1:24-cv-01188 (docket and filings).